Literature DB >> 2556277

In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.

M D Kitzis1, B Ferré, A Coutrot, J F Acar, L Gutmann.   

Abstract

Combinations of different beta-lactam antibiotics, including cefotaxime, with three beta-lactamase inhibitors were tested against cephalosporinase producing bacterial strains. The most significant antagonism was obtained with a combination of clavulanic acid and cefotaxime, while almost no antagonism was observed with sulbactam and tazobactam. In strains belonging to five different species there was a correlation between the levels of cephalosporinase produced after exposure to different concentrations of inhibitors and the MICs of cefotaxime combined with the same concentrations of inhibitors. It is concluded that there is little likelihood of antagonism between beta-lactam antibiotics and sulbactam or tazobactam.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556277     DOI: 10.1007/BF02185845

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa.

Authors:  F Tausk; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

2.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

3.  Ability of newer beta-lactam antibiotics to induce beta-lactamase production in Enterobacter cloacae.

Authors:  R L Then
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

4.  Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid.

Authors:  S Bennett; R Wise; D Weston; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

5.  Kinetic studies on inactivation of Citrobacter freundii cephalosporinase by sulbactam.

Authors:  A Yamaguchi; T Hirata; T Sawai
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

Review 6.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa.

Authors:  S C Aronoff; D M Shlaes
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

8.  Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa.

Authors:  D M Livermore; Y J Yang
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

9.  The effects of clavulanic acid and sulbactam on beta-lactamase biosynthesis.

Authors:  T H Farmer; C Reading
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

10.  Induction of chromosomal beta-lactamases by different concentrations of clavulanic acid in combination with ticarcillin.

Authors:  E E Stobberingh
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

View more
  8 in total

1.  Evaluation of the automated phoenix system for potential routine use in the clinical microbiology laboratory.

Authors:  J-L Donay; D Mathieu; P Fernandes; C Prégermain; P Bruel; A Wargnier; I Casin; F X Weill; P H Lagrange; J L Herrmann
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  James A Karlowsky; Mellany K Weaver; Clyde Thornsberry; Michael J Dowzicky; Mark E Jones; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

Review 4.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 5.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 6.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

7.  The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β-lactamase in Enterobacter cloacae.

Authors:  Christine Miossec; Monique Claudon; Premavathy Levasseur; Michael T Black
Journal:  Infect Drug Resist       Date:  2013-12-03       Impact factor: 4.003

8.  Antimicrobial prescriptions and adherence to prudent use guidelines for selected canine diseases in Switzerland in 2016.

Authors:  Bérénice Lutz; Claudia Lehner; Kira Schmitt; Barbara Willi; Gertraud Schüpbach; Meike Mevissen; Ruth Peter; Cedric Müntener; Hanspeter Naegeli; Simone Schuller
Journal:  Vet Rec Open       Date:  2020-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.